Cargando…

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?

Novel cardioprotective agents are needed in both heart failure (HF) and myocardial infarction. Increasing evidence from cellular studies and animal models indicate protective effects of phosphodiesterase-5 (PDE5) inhibitors, drugs usually reserved as treatments of erectile dysfunction and pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hutchings, David Charles, Anderson, Simon George, Caldwell, Jessica L, Trafford, Andrew W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204975/ https://www.ncbi.nlm.nih.gov/pubmed/29519873 http://dx.doi.org/10.1136/heartjnl-2017-312865

Ejemplares similares

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
por: Anderson, Simon G, et al.
Publicado: (2016)

Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure
por: Lawless, Michael, et al.
Publicado: (2019)

The Control of Diastolic Calcium in the Heart: Basic Mechanisms and Functional Implications
por: Eisner, David A., et al.
Publicado: (2020)

Phosphodiesterase-5 inhibition and cardioprotection: potential role of hydrogen sulfide
por: Kukreja, Rakesh C, et al.
Publicado: (2009)

Phosphodiesterase-5 Inhibition Mimics Intermittent Reoxygenation and Improves Cardioprotection in the Hypoxic Myocardium
por: Milano, Giuseppina, et al.
Publicado: (2011)

Calcium and Excitation-Contraction Coupling in the Heart
por: Eisner, David A., et al.
Publicado: (2017)

Correction: Phosphodiesterase-5 Inhibition Mimics Intermittent Reoxygenation and Improves Cardioprotection in the Hypoxic Myocardium
por: Milano, Giuseppina, et al.
Publicado: (2012)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Calcium in the Pathophysiology of Atrial Fibrillation and Heart Failure
por: Denham, Nathan C., et al.
Publicado: (2018)

The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart
por: Tate, Mitchel, et al.
Publicado: (2019)

Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials
por: Giannetta, Elisa, et al.
Publicado: (2014)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca(2+) Content
por: Hutchings, David C., et al.
Publicado: (2021)

Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia
por: Bork, Nadja I., et al.
Publicado: (2021)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Contribution of sewage to occurrence of phosphodiesterase-5 inhibitors in natural water
por: Hong, Youngmin, et al.
Publicado: (2021)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design
por: Amedro, Pascal, et al.
Publicado: (2020)

Contemporary cost-analysis comparison of direct-to-consumer vs. traditional prescriptions of phosphodiesterase-5 inhibitors
por: Schneider, Douglas, et al.
Publicado: (2022)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
por: Halverscheid, Leonie, et al.
Publicado: (2009)

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Pharmacophore elucidation and molecular docking studies on phosphodiesterase-5 inhibitors
por: Radwan, Awwad Abdoh
Publicado: (2015)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
por: ElHady, Ahmed K., et al.
Publicado: (2023)

Coupling of conformational dynamics and inhibitor binding in the phosphodiesterase‐5 family
por: Tripathi, Shubhandra, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis
por: Machen, G. Luke, et al.
Publicado: (2017)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Cardioprotection in right heart failure
por: Boengler, Kerstin, et al.
Publicado: (2020)

Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity
por: Tardif, Steve, et al.
Publicado: (2014)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b2024n0bjn27mchja5m7mbtnpu